Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study

Brown, David M.; Heier, Jeffrey S.; Clark, W. Lloyd; Boyer, David S.; Vitti, Robert; Berliner, Alyson J.; Zeitz, Oliver; Sandbrink, Rupert; Zhu, Xiaoping; Haller, Julia A.

doi:10.1016/j.ajo.2012.09.026

Cited by 324 publications

(319 citation statements)

References 17 publications

Supporting

Mentioning

259

Contrasting

Unclassified

Order By: Relevance

“…The distribution across all retinal layersto the choroidal vasculature is facilitated [11,12] . Aflibercept is a 115 KDareceptor Fc fusion protein, composed of domains of the human VEGF receptor 1 and 2, which shows a higher affinity to bind VEGF compared to ranibizumab and bevacizumab [1,[13][14][15] . Because of the intact Fc region, afliberceptis likely to besubject to FcRn recycling, which is supported by aserum half-life of approximately 5-6 days followingintravenous administration [13,16] .…”

Section: Efficacymentioning

confidence: 99%

Anti-VEGF Therapy for Retinal Vein Occlusion

Danzmann¹,

Pielen²,

Bajor³

2016

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

Current recommendations for treatment of macular edema secondary to BRVO or CRVO favour intravitreal anti-VEGF agents compared to intravitreal steroids. An upload of 3 injections is reasonable to address intravitreal VEGF levels. Prognosis for visual improvement is good and time to treatment is crucial. There is evidence that an early targeted laser photocoagulation of ischemic areas may lead to additional treatment effects, less injections and improved prognosis if administered early after RVO. In the course of the disease patients must be frequently monitored for recurrence of edema to initiate re-treatment and for conversion to ischemic RVO. Ischemia, proliferations and rubeosisiridis must not be treated with intravitreal anti-VEGF alone. Laser treatment of peripheral retina remains the standard-of-care to treat ischemia. In this article we review up-to-date information on intravitreal anti-VEGF therapy in RVO, international guidelines, safety and efficacy of treatment. We discuss new insights on factors that may improve prognosis or burden of intravitreal treatment. And we discuss the role of ischemia in RVO.

show abstract

Section: Efficacymentioning

confidence: 99%

Anti-VEGF Therapy for Retinal Vein Occlusion

Danzmann¹,

Pielen²,

Bajor³

2016

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

show abstract

“…The first six months of the both studies were identical, patients were randomized into two groups -receiving intravitreal aflibercept 2 mg monthly and those who received intravitreal placebomonthly.In the second six months,GALILEO study was design to continue treatment group with aflibercept on the PRN (provided as needed) basis and the control group with placebo (24), while in the COPERNICUS study (23), all patients were treated with aflibercept on a PRN basis.In both the COPERNICUS and GALILEO studies, aflibercept injection resulted in an improvement in visual acuity of .15 letters in 56.1% and 60.2% of patients, respectively, at week 24 compared with those receiving sham injections (12.3% and 22.1%, respectively). At week 52 in the COPERNICUS study, the improvement in visual acuity was 55.3% in the aflibercept/aflibercept PRN patients compared with 30.1% in the placebo/aflibercept PRN patients.…”

Section: Macular Edema Following Central Retinal Vein Occlusion (Crvo)mentioning

confidence: 99%

New approach in the treatment of ophthalmic neovascular disorders: using fusion protein aflibercept

Georgiev

Georgiev²,

Georgiev³

2014

Biomedical Reviews

View full text Add to dashboard Cite

show abstract

“…Bevacizumab, ranibizumab, and aflibercept are the 3 anti-VEGF agents used in treatment. The first drug is used off-label; the others are approved for this purpose (2,8,(9)(10)(11)(12). In pivotal multicenter studies in which strict follow-up and treatment criteria were observed, successful treatment outcomes have been reported (9)(10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study

Özkaya¹

2017

Beyoglu Eye J

View full text Add to dashboard Cite

Objectives:The present study is comparison of efficacy of ranibizumab and aflibercept in the treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in real life. Methods: Design was retrospective, case-control study. Treatment naïve RVO patients with ME who were treated with ranibizumab or aflibercept and had minimum follow-up time of 6 months were included. Primary outcome measures were changes in best corrected visual acuity (BCVA) and central retinal thickness (CRT). Secondary outcome measure was number of injections administered. Results: Mean baseline, month 3, and month 6 BCVA in ranibizumab group was 0.95±0.61-, 0.50±0.30-, and 0.66±0.58 logarithm of the minimum angle of resolution (LogMAR), respectively. Mean baseline, month 3, and month 6 BCVA in aflibercept group was 0.85±0.65-, 0.61±0.58-, and 0.65±0.55 LogMAR, respectively. Mean baseline, month 3, and month 6 CRT in ranibizumab group was 598±189-, 473±162-, and 359±134 μm, respectively. Mean baseline, month 3, and month 6 CRT in aflibercept group was 512±141-, 345±154-, and 374±172 μm, respectively. Mean number of injections was 2.7±0.8 for ranibizumab group, and 2.2±1.0 for aflibercept group (p=0.08). Conclusion: Ranibizumab and aflibercept are both effective agents in the treatment of ME secondary to RVO. Visit and injection figures were lower than those reported in prospective, multicenter studies, as expected, but functional and anatomical outcomes were comparable.

show abstract

Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study

Cited by 324 publications

References 17 publications

Anti-VEGF Therapy for Retinal Vein Occlusion

Anti-VEGF Therapy for Retinal Vein Occlusion

New approach in the treatment of ophthalmic neovascular disorders: using fusion protein aflibercept

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study

Contact Info

Product

Resources

About